denagard 200 mg/ml solution for injection
novartis animal health uk ltd - tiamulin - solution for injection - 200 mg/ml - tiamulin - porcine - antibacterial
denagard 200 mg/ml solution for injection
elanco europe ltd - tiamulin base ph. eur. (equivalent to tiamulin hydrogen fumarate) - solution for injection - 200 mg/ml - tiamulin - porcine - antibacterial
denagard 200 mg/ml solution for injection
elanco europe ltd - tiamulin base ph. eur. (equivalent to tiamulin hydrogen fumarate) - solution for injection - 200 mg/ml - tiamulin - porcine - antibacterial
marbocyl 2% solution for injection
vetoquinol sa - marbofloxacin - solution for injection - antimicrobial - cattle, pigs
marbocyl 2% solution for injection
vetoquinol uk ltd - marbofloxacin - solution for injection - antimicrobial - cattle, pigs
levetiracetam- levetiracetam injection injection, solution, concentrate
jubilant cadista pharmaceuticals inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 100 mg in 1 ml - levetiracetam injection, usp is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy. levetiracetam injection, usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam injection, usp is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam injection, usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam injection, usp is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. levetiracetam injection, usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam injection is
bretylium tosylate- bretylium tosylate injection
pharmaceutics international, inc. (pii) - bretylium tosylate (unii: 78zp3yr353) (bretylium - unii:rzr75eq2kj) - bretylium tosylate injection, usp is indicated in the prophylaxis and therapy of ventricular fibrillation. bretylium tosylate injection, usp is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. use of bretylium tosylate injection, usp should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. following injection of bretylium tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. the delay in effect appears to be longer after intramuscular than after intravenous injection. there are no contraindications to use in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, excep
disipal tablets 50 milligram
yamanouchi pharma ltd - orphenadrine hydrochloride - tablets - 50 milligram
disipal withdrawn form
yamanouchi pharma ltd - withdrawn form
disipal tablets 50mg
central procurement & supplies unit - orphenadrine hydrochloride - tablet - orphenadrine hydrochloride 50 milligram(s) - anti-parkinson drugs